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Abstract
Background
Nifurtimox eflornithine combination therapy (NECT) to treat human African trypanosomiasis
(HAT), commonly called sleeping sickness, was added to the World Health Organisation’s
(WHO) Essential Medicines List in 2009 and to the Paediatric List in 2012. NECT was further
tested and documented in a phase IIIb clinical trial in the Democratic Republic of Congo
(DRC) assessing the safety, effectiveness, and feasibility of implementation under field con-
ditions (NECT-FIELD study). This trial brought a unique possibility to examine concomitant
drug management.
Methodology/Principal findings
This is a secondary analysis of the NECT-FIELD study where 629 second stage gambiense
HAT patients were treated with NECT, including children and pregnant and breastfeeding
women in six general reference hospitals located in two provinces. Concomitant drugs were
prescribed by the local investigators as needed. Patients underwent daily evaluations,
including vital signs, physical examination, and adverse event monitoring. Concomitant
medication was documented from admission to discharge. Patients’ clinical profiles on
admission and safety profile during specific HAT treatment were similar to previously pub-
lished reports. Prescribed concomitant medications administered during the hospitalization
period, before, during, and immediately after NECT treatment, were mainly analgesics/anti-
pyretics, anthelmintics, antimalarials, antiemetics, and sedatives. Use of antibiotics was rea-
sonable and antibiotics were often prescribed to treat cellulitis and respiratory tract
infections. Prevention and treatment of neurological conditions such as convulsions, loss of
consciousness, and coma was used in approximately 5% of patients.
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Conclusions/Significance
The prescription of concomitant treatments was coherent with the clinical and safety profile
of the patients. However, some prescription habits would need to be adapted in the future to
the evolving available pharmacopoeia. A list of minimal essential medication that should be
available at no cost to patients in treatment wards is proposed to help the different actors to
plan, manage, and adequately fund drug supplies for advanced HAT infected patients.
Trial registration number
The initial study was registered at ClinicalTrials.gov, number NCT00906880.
Author summary
Sleeping sickness is a neglected tropical disease caused by a parasite, the trypanosome,
transmitted by the tse-tse fly. It affects people in Sub-Saharan Africa, most of them living
in poor rural settings with limited access to healthcare. If the disease remains untreated, it
usually progresses from a haemo-lymphatic invasion into a second stage or neuro-enceph-
alitic infection evolving into coma and death. When these second stage patients are
referred to treatment centres, the disease is often advanced. Therefore, on top of sleeping
sickness treatment, additional care and medications are regularly required. We report
here the concomitant medications that were prescribed to second stage sleeping sickness
patients, including vulnerable populations such as children, and pregnant and breastfeed-
ing women, in the context of a phase IIIb trial assessing the safety, effectiveness, and feasi-
bility of implementation of the Nifurtimox Eflornithine Combination Therapy (NECT) in
field conditions. Our objective is to provide evidence to national health systems or private
actors to plan and fund their essential medicine supplies adapted to second stage sleeping
sickness patients.
Introduction
Human African trypanosomiasis (HAT), also called sleeping sickness, affects people in sub-
Saharan Africa who often live in remote or insecure areas with limited access to healthcare.
The disease is caused by a trypanosome infection after a bite from a tse-tse fly and evolves
from a haemo-lymphatic invasion (first stage) into a neuro-encephalitic infection (second
stage) that leads to severe sleep disturbances, neurological and psychiatric disorders, coma,
and in most cases to death if untreated [1]. Until 2009, treatment for the second stage T.b. gam-
biense HAT was limited to melarsoprol, an arsenic derivative with high toxicity [2] and in
some areas, reduced efficacy [3–5], or eflornithine monotherapy, a burdensome treatment
consisting in 56 slow infusions over 2 weeks [6].
Nifurtimox Eflornithine Combination Therapy (NECT) was added to the World Health
Organization’s Essential Medicines List (WHO EML) in 2009 [7] and to the Paediatric WHO
EML in 2012 [8]. Since then, a new oral molecule, fexinidazole, has been further assessed and
was granted a positive opinion from the European Medicine Agency (EMA) for the treatment
of first and second stage HAT in 2018 [9, 10]. Following the introduction of fexinidazole,
NECT will still remain the first choice treatment in patients presenting a clinical picture con-
sistent with severe second stage HAT with� 100 white blood cell (WBC)/μL in the cerebrospi-
nal fluid (CSF), or those unable to eat. It also remains the first choice for pediatric patients
Prescription of concomitant medications in second stage HAT patients treated with NECT
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008028 January 27, 2020 2 / 13
share personal medical information was not
received from the enrolled subjects. Data can be
made available to qualified researchers upon
request after signing a confidentiality agreement.
Data requests may be sent to the Department of
Medicine, Swiss Tropical and Public Health
Institute (medres@swisstph.ch).
Funding: This secondary analysis was funded by
DNDi. The NECT-FIELD study was sponsored by
UK aid, UK; the Swiss Agency for Development and
Cooperation (SDC), Switzerland; Me´decins Sans
Frontières (MSF) International and other private
foundations. The NECT-FIELD study funders had
no role in study design, analysis, decision to
publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
younger than 6 years old or weighting less than 20 kg presenting with> 5 WBC/μL or try-
panosomes in the CSF [11, 12].
From 2009 to 2012, NECT was tested and documented in a phase IIIb clinical trial (NECT-
FIELD study) in the Democratic Republic of Congo (DRC) [13]. In the NECT-FIELD study,
the safety, effectiveness, and feasibility of implementation under field conditions were assessed.
The in-hospital safety profile of NECT administered to a wide population, including vulnera-
ble people such as children, and pregnant and breastfeeding women, was already published by
Schmid et al [13], while the 24-months effectiveness analysis is under preparation and will be
submitted for publication.
Before and during the HAT specific treatment the patients received an array of concomitant
medication to treat co-morbidities or manage adverse events. The NECT-FIELD study
brought a unique opportunity to examine in-hospital patient management, given concomitant
diseases and adverse events in second stage HAT patients.
The present analysis describes the concomitant medication prescribed during hospitaliza-
tion before and during treatment with NECT. In our knowledge, this has never been done so
far in any clinical trial involving second stage HAT patients. The main objective of this work is
to help national health systems or private actors to plan, develop, and update the essential
medicine supplies adapted to their second stage HAT gambiense patients including vulnerable
populations such as children as well as pregnant and breastfeeding women.
Methods
Design and study population
This is a secondary analysis of the NECT-FIELD study conducted between 2009 and 2012 in
six HAT treatment centres located in reference district hospitals in the DRC and included 629
patients treated with NECT. The design, methods, and in-hospital safety results of the NECT-
FIELD study are described in the published report by Schmid et al [13]. Briefly, all second
stage HAT patients admitted to the treatment centres received NECT, the co-administration
of nifurtimox (oral 15 mg/kg/day, three times a day) for 10 days and eflornithine (slow intrave-
nous infusions, 400 mg/kg/day, twice a day) for 7 days. All patients were hospitalised during
the entire treatment period.
Prior to NECT, the patients received standard pre-treatment according to the national
guidelines, consisting of antimalarial, anthelminthic, and, if required, antipyretic/analgesic
medication. Concomitant medication was prescribed according to the decision of the investi-
gator and the local guidelines. An emergency pharmacy for eventual life-threatening issues
was provided by the study coordination to the Investigators while the other drugs were rou-
tinely supplied by the national HAT program or the hospital pharmacy.
Collected data
Patients underwent daily evaluations, including vital signs, physical examination, and adverse
event (AE) monitoring. The concomitant medications were documented and details such as the
reason for use, dates, dosages, and route and duration of administration were recorded. AEs
and their severity were reported from the first day of treatment until discharge from hospital
and were assessed along with their severity and possible relation to the study treatment [14].
The AEs and concomitant medications were coded with the MedDRA dictionary (version 11)
and the WHO-Drug dictionary (version Q2.06) respectively. AEs observed in� 5% of the
patients and concomitant medications prescribed in� 2.5% have been included in the result
tables for the assessment of concomitant medication prescriptions. AEs and concomitant drugs
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that appeared with lower frequencies but were of medical relevance were included after discus-
sion between AK and OVM.
Statistics
The main analysis set is the intention to treat (ITT) population, which includes all subjects
who received at least one dose of study drug. Statistical evaluations are descriptive. Means,
standard deviations, and number of patients are provided for continuous variables, as well as
frequency distributions for binary and categorical variables. Statistical analyses were per-
formed using the SAS software version 9.1 (SAS Institute, Cary, NC) and Epi Info 7.0.
Ethical considerations
The NECT-FIELD study received approval from two Ethics Committees: the Ethics Commit-
tee of both cantons of Basel (EKBB, Basel, Switzerland; 26 February, 2009) and the local Ethics
Committee in the DRC (Comite d’ethique sur la Trypanosomiase Humaine Africaine, Kin-
shasa, Democratic Republic of the Congo, 7 May 2009). Eligible patients provided written
informed consent before enrolment into the study. In case of minors, severely ill, or mentally
impaired patients unable to fully consent, written informed consent was obtained from her/his
parent(s)/guardian(s). Whenever possible, depending on age and level of understanding, the
children received the information and their assent was obtained.
Results
Study population and clinical profile on admission
Of the 629 patients included in this analysis, 100 were children below 12 years of age, 33 were
breastfeeding women, and 14 were pregnant women (Table 1). The patient flow is published
Table 1. Demographic characteristics of the study population.
Characteristics Number of patients treated n (%)�
Total number of patients (N) 629
Male/female ratio 1.3
Children 0–11 years 100 (15.9)
Adolescents/adults > 11 years 529 (84.1)
Breastfeeding women 33 (5.2)
Pregnant women 14 (2.2)
Age, mean (SD) years# 30 (16.2)
Median 28
Range (min-max) 1–77
Study sites
Kasai Oriental Province
Dipumba 146 (23.2)
Katanda 132 (21.0)
Ngandajika 94 (14.9)
Bandundu Province
Bandundu 98 (15.6)
Kwamouth 97 (15.4)
Yasa Bonga 62 (9.9)
�Unless otherwise specified
#age unknown for 2 patients
https://doi.org/10.1371/journal.pntd.0008028.t001
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in the in-hospital safety report [13]. HAT signs and symptoms reported by the patients on
admission are shown in Table 2.
Treatment emergent adverse events
The reporting of treatment emergent AEs showed that above all, patients developed gastrointesti-
nal disorders including nausea and vomiting, general disorders like fever, and neurological and
psychiatric disorders like asthenia, headaches, dizziness, convulsions, insomnia, and agitation that
are difficult to distinguish from the disease itself (Table 3). Less frequently but of medical impor-
tance, potentially severe or life-threatening AEs if not treated such as coma, loss of consciousness,
specific psychiatric disorders, infections, and cardiac disorders were also observed.
Prescription of concomitant medication
Medication given before study treatment started consisted mainly in anti-parasitic pre-treat-
ment according to HAT national guidelines, usually 1–3 days before the start of the first dose
of NECT and lasting normally 3 days. This anti-parasitic pre-treatment usually comprised an
antimalarial and an anthelmintic (Table 4). Depending on the treatment centre, paracetamol
was either routinely administered after the lumbar puncture or when the patients complained
of headaches. The majority of the patients received the antimalarial pre-treatment sulfadoxine/
pyrimethamine combination, with the exception of one centre, where patients received artesu-
nate. Severe malaria cases were managed at all sites with intravenous isotonic quinine infusion.
Concomitant medication during NECT was common in all study populations and most
patients received at least one concomitant medication (Table 4). Administered treatments
were mainly analgesics and antipyretics, anthelmintics, antiemetics, and sedatives.
The most frequently administered antibiotics during NECT were amoxicillin, ampicillin,
ciprofloxacin, and gentamicin and were mainly prescribed to treat injection site infections
(including cellulitis) or respiratory tract infections.
Discussion
We report an evaluation of the concomitant medication prescribed to the 629 patients
included in the NECT-FIELD study conducted at six HAT treatment centres in the DRC [13].
Table 2. HAT signs and symptoms reported by the patient on admission.
Percentage of patients with (%)� Children
0–11 years
Adolescents & adults
>11 years
Breast-feeding women Pregnant women All patients
N = 100 N = 482ǂ N = 33 N = 14 N = 629
Sleeping disorders 80.0 80.5 72.7 64.3 79.7
Headache 50.0 78.6 84.8 92.9 74.7
Asthenia 44.0 64.5 54.5 92.9 61.4
Fever history 77.0 56.0 42.4 71.4 59.0
Pruritus 44.0 61.8 57.6 35.7 58.2
Weight loss 46.0 55.8 54.5 78.6 54.7
Tremor 35.0 45.9 30.3 57.1 43.6
Walking disorder 28.0 45.0 15.2 57.1 41.0
Behavioural disorder 42.0 32.8 24.2 21.4 33.5
Convulsions 15.0 3.5 3.0 7.1 5.4
�Unless otherwise specified
ǂall adolescents and adults except breastfeeding / pregnant women
https://doi.org/10.1371/journal.pntd.0008028.t002
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Table 3. Treatment emergent adverse events (AEs).
Percentage of patients with (%)� Children
0–11 years
Adolescents & adults
>11 years
Breast-feeding women Pregnant women All patients
N = 100 N = 482ǂ N = 33 N = 14 N = 629
Treatment emergent adverse events (AEs)
Patients with at least 1 adverse event 92.0 92.1 84.8 100.0 91.9
Death 0 1.9 0 7.1 1.6
Gastrointestinal disorders 43.0 63.9 66.7 92.9 61.4
Vomiting 31.0 43.6 57.6 78.6 43.1
Nausea 13.0 22.0 6.1 21.4 19.7
Colitis or diarrhoea 13.0 13.3 6.1 7.1 12.7
Pain and discomfort of the
gastrointestinal tract%
5.0 16.2 18.2 35.7 14.9
General disorders and administration site condition 57.0 41.7 60.6 85.7 46.1
Fever 44.0 25.9 42.4 28.6 29.7
Asthenia 13.0 16.8 27.3 57.1 17.6
Injection site disorders& 7.0 4.8 6.1 7.1 5.2
Nervous system disorders 21.0 37.1 24.2 57.1 34.3
Headache 8.0 15.4 12.1 35.7 14.5
Dizziness 0 13.1 6.1 14.3 10.7
Convulsions 10.0 9.1 9.1 0 9.1
Tremor 4.0 3.3 0 0 3.2
Coma or loss of consciousness 1.0 1.7 3.0 7.1 1.7
Metabolism and nutrition disorders 22.0 27.8 12.1 28.6 26.1
Anorexia 21.0 27.2 9.1 28.6 25.3
Psychiatric disorders 9.0 17.6 12.1 0 17.6
Insomnia 3.0 7.7 0 0 6.4
Agitation 5.0 5.6 12.1 0 5.7
Behavioural disorders 0 1.9 0 0 1.4
Mood disorders 1.0 1.0 3.0 0 1.1
Mental confusion 1.0 0.8 0 0 0.8
Hallucinations or delirium 0 1.5 0 0 1.1
Psychosis or acute psychosis 0 0.2 3.0 0 0.3
Depression 0 0.2 0 0 0.2
Musculoskeletal and connective tissue disorders 4.0 15.4 15.2 21.4 13.7
Lumbago 2.0 6.2 6.1 21.4 5.9
Neck pain 0 3.9 3.0 0 3.2
Skin and sub-cutaneous tissue disorders 9.0 9.8 6.1 7.1 9.4
Pruritus or cutaneous pruritus 7.0 5.8 3.0 0 5.1
Dermatitis or cutaneous eruption 2.0 1.0 0 0 1.1
Vascular disorders 3.0 8.3 6.1 14.3 7.5
Hypotension 3.0 4.8 6.1 14.3 4.8
Hypertension 0 2.9 0 0 2.2
Cardiac disorders 4.0 7.9 3.0 7.1 7.0
Palpitation or arrhythmia 3.0 5.8 3.0 0 5.1
Bradycardia 0 1.2 0 0 1.0
Tachycardia 1.0 0.8 0 7.1 1.0
Infections and infestations 8.0 4.6 3.0 14.3 5.2
Respiratory infections$ 2.0 1.0 7.1 0 1.3
Cellulitis 1.0 1.0 0 7.1 1.1
(Continued)
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The patients’ clinical and safety profiles were characteristic of second stage HAT patients [15–
19]. It therefore appears that drugs were not only used to treat the treatment emergent AEs but
also the symptoms related to the disease itself.
The known bone marrow toxicity of eflornithine [6] and the repeated eflornithine perfu-
sions raised some concerns about the increased risk of bacterial infections in the field and the
consequent use of antibiotics. The proportion of treated patients with antibiotics remained
reasonable in our context which is reassuring.
Another concern in second stage patients are the neurological complications. Dexametha-
sone and Ringer lactate, administered intravenously in 5.2% and 2.7% of the patients, are
drugs that are used in this setting to treat or prevent convulsions and coma. It seems that they
have been administered at an appropriate frequency.
The concomitant drugs were prescribed in coherence with the clinical and safety profile of
the study population even if some prescription habits would need to be improved. For exam-
ple, one centre provided artesunate monotherapy as standard pre-treatment which is subopti-
mal considering the general recommendation of using it in combination. It also appeared that
some classical field prescription practices such as the utilisation of metamizol and papaverine,
administered in 25.4% and 2.5% of the patients respectively might be considered as suboptimal
at first sight. However, after discussion with the investigators these choices were either driven
by the availability of drugs at the centres or by some medical decisions. At the time of the
study, between 2008 and 2010, metamizol, due to the suspicion of bone marrow toxicity, was
only recommended when other antipyretics were inefficient or when the fever needed to be
brought down urgently, above all in children. In this specific population, metamizol was often
preferred because the intravenous route made its administration easier. Neverthelesss, meta-
mizol has been banned in DRC since and treatment with NSAID such as ibuprofen or diclofe-
nac would therefore be recommended today. Papaverine was administered preferably to
pregnant women to treat gastrointestinal disorders such as nausea and vomiting, because
metoclopramide is contra-indicated in this population.
In a low-resource setting, drug supply choices of the centers may partially be driven by the
scarce financial resources but also by their availability at the hospital and surrounding or if the
drug was supplied by the national HAT program. For example, the choice to prescribe levami-
sole and cotrimoxazole was mainly driven by the fact that these drugs were supplied by the
HAT national program and their availability. However, data on concomitant drug supply and
Table 3. (Continued)
Percentage of patients with (%)� Children
0–11 years
Adolescents & adults
>11 years
Breast-feeding women Pregnant women All patients
N = 100 N = 482ǂ N = 33 N = 14 N = 629
Malaria 1.0 0.6 3.0 0 0.6
Septic shock 0 0.2 0 7.1 0.3
Blood and lymphatic system disorders 3.0 1.2 0 7.1 1.6
Anaemia 2.0 1.0 0 7.1 1.3
�Unless otherwise specified
ǂall adolescents and adults except breastfeeding / pregnant women
%the following AEs have been grouped under Pain and discomfort of the gastrointestinal tract: heartburn, lower abdominal pain, left hypochondrium pain, abdominal
pain, dyspepsia, dysphagia, epigastralgia, upset stomach
& the following AEs have been grouped under injection site disorders: pain at the injection site, pain at the catheter site, extravasation and injection site reaction.
$including pneumonia and bronchopneumonia
https://doi.org/10.1371/journal.pntd.0008028.t003
Prescription of concomitant medications in second stage HAT patients treated with NECT
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008028 January 27, 2020 7 / 13
Table 4. Prescription of concomitant medication.
Percentage of patients treated with (%) Children
0–11 years
Adolescents & adults
> 11 years
Breast-feeding women Pregnant women All patients
N = 100 N = 482� N = 33 N = 14 N = 629
(A) BEFORE HAT TREATMENT
Patients with at least 1 treatment 89.0 85.3 72.7 85.7 85.2
Anthelmintics
Mebendazole 33.0 32.8 27.3 28.6 32.4
Antiprotozoals
Sulfadoxine/pyrimethymine 73.0 76.1 60.6 85.7 75.0
Artesunate 7.0 6.8 12.1 0 7.0
Quinine 8.0 1.7 0 0 2.5
Analgesics, antipyretics
Paracetamol 5.0 9.1 12.1 7.1 8.6
(B) DURING NECT TREATMENT
Patients with at least 1 treatment 90.0 95.4 97.0 100.0 94.8
Antibacterials
Amoxicillin 8.0 5.8 3.0 7.1 6.0
Sulfamethoxazole/trimethoprim 5.0 5.4 3.0 0 5.1
Ciprofloxacin 2.0 2.1 3.0 0 2.1
Gentamicin 1.0 1.5 0 7.1 1.4
Ampicillin 1.0 1.5 0 0 1.3
Antiprotozoals
Sulfadoxine/pyrimethymine 10.0 14.5 24.2 14.3 14.3
Quinine 5.0 2.9 6.1 0 3.3
Metronidazole 3.0 2.5 3.0 0 2.5
Artesunate 0 1.2 0 7.1 1.1
Anthelmintics
Mebendazole 57.0 53.3 51.5 50.0 53.7
Levamisole 8.0 12.7 18.2 14.3 12.2
Scabicides
Benzyl benzoate 5.0 5.2 0 0 4.8
Analgesics, antipyretics
Paracetamol 33.0 33.4 48.5 50.0 34.5
Metamizole 30.0 23.2 39.4 35.7 25.4
Acetylsalicylic acid 12.0 6.0 3.0 0 6.7
Anti-inflammatory medicines
Diclofenac 0 2.9 3.0 0 2.4
Antihistamines
Promethazine 4.0 6.4 6.1 0 5.9
Chlorphenamine 1.0 2.5 0 0 2.1
Dexchlorpheniramine 0 2.3 0 0 1.7
Corticosteroids
Dexamethasone 6.0 5.4 0 7.1 5.2
Hydrocortisone 2.0 4.4 6.1 7.1 4.1
Cardiovascular medicines
Furosemide 1.0 2.9 0 0 2.4
Gastrointestinal medicines
Metoclopramide 6.0 10.2 12.1 7.1 9.5
(Continued)
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availability have not been collected at the time of the NECT-FIELD study. Therefore we cannot
conclude on the relative importance of how lack of resources, supply chain, availability, and
access influenced the utilization of concomitant drugs in our setting.
Another limitation of this present analysis is the replication and generalisability of the results,
as we are only relying on the prescription habits of the clinicians and clinical teams of our six
study sites. In our knowledge, this is the first study reporting the real-life prescription of concomi-
tant medicine during second stage sleeping sickness treatment. In order to reassure our findings
we compared the AEs reported in recent clinical trial [10, 16] and field cohorts [19] by compiling
together the safety profiles in Table 5. Results suggests that the comorbidity and AE profile of
Table 4. (Continued)
Percentage of patients treated with (%) Children
0–11 years
Adolescents & adults
> 11 years
Breast-feeding women Pregnant women All patients
N = 100 N = 482� N = 33 N = 14 N = 629
Oral rehydration solution 7.0 5.4 3.0 7.1 5.6
Aluminium Hydroxide 0 3.1 3.0 0 2.5
Papaverine 1.0 2.3 3.0 21.4 2.5
Nervous system medicines
Diazepam 14.0 18.5 15.2 0 17.2
Phenobarbital 1.0 4.8 0 7.1 4.0
Chlorpromazine 2.0 3.9 9.1 0 3.8
Vitamins
Multivitamins 5.0 8.5 6.1 21.4 8.1
Vitamin B6 complex 3.0 5.8 6.1 7.1 5.4
Perfusion solutions
Hypertonic glucose 7.0 7.5 9.1 14.3 7.6
NaCl 0 4.1 0 14.3 3.5
Ringer lactate 1.0 2.9 3.0 7.1 2.7
Glucose 2.0 1.9 6.1 0 2.1
�All adolescents and adults except breastfeeding / pregnant women
https://doi.org/10.1371/journal.pntd.0008028.t004
Table 5. Overview of adverse event profile during HAT therapy in published clinical trials.
Percentage of patients with (%) NECT vs DFMO
Phase III trial [16] � ,#
NECT MSF
[19] #
Fexinidazole vs NECT Phase III trial [10]
NECT
N = 143
DFMO
N = 143
NECT
N = 684
Fexinidazole N = 264 NECT N = 130
Gastrointestinal disorders
Vomiting 48$ 20$ 39 28 29
Nausea $ $ 8 26 19
Diarrhoea 6 29 7 3 4
Abdominal pain 25 29 41 10 12
General disorders and administration site condition
Fever 26 43 - 9 19
Asthenia 24 20 - 23 14
Fatigue - - 11 - -
Injection site disorders 10 11 - - -
(Continued)
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patients were comparable among all these studies and that concomitant medication needs would
be more or less be similar among the different HAT treatment options and treatment centers.
In order to better manage the clinical profile of second stage HAT patients and the AEs of
NECT, we propose a list of minimal essential drugs based on the results of this analysis and on
the WHO EML that should be available at no cost to the patient night and day in treatment
wards (Table 6) [20]. This recommendation provides new evidence to programs, health sys-
tems, donors, and other actors to plan, fund, and supply the essential medicines adapted to
treat second stage sleeping sickness patients.
Table 5. (Continued)
Percentage of patients with (%) NECT vs DFMO
Phase III trial [16] � ,#
NECT MSF
[19] #
Fexinidazole vs NECT Phase III trial [10]
NECT
N = 143
DFMO
N = 143
NECT
N = 684
Fexinidazole N = 264 NECT N = 130
Nervous system disorders
Headache 39 46 30 35 24
Dizziness 18 17 20 19 13
Convulsions 13 9 4 2 8
Tremor 6 1 7 22 11
Coma or loss of consciousness 1 2 - - -
Metabolism and nutrition disorders
Anorexia or decreased appetite 25 14 21 21 19
Psychiatric disorders
Insomnia 10 10 12 28 12
Agitation 3 8 - 4 1
Mood disorders, anxiety, or depression 1 1 8 4 -
Mental confusion 4 1 - - -
Hallucinations, delirium, or psychosis 1 1 3 3 3
Musculoskeletal and connective tissue disorders
Musculoskeletal pain 30 30 25 - -
Back pain - - - 11 9
Neck pain - - - 9 5
Skin and sub-cutaneous tissue disorders
Pruritus or cutaneous pruritus 9 19 4 4 3
Dermatitis or skin rash 3 14 - - -
Vascular disorders
Hypotension 4 3 - - -
Hypertension 4 13 - 5 1
Cardiac disorders
Palpitation or arrhythmia 19 22 - 5 4
Infections and infestations
All kind of infections 10 18 - 8 6
Blood and lymphatic system disorders
Anaemia - - - 9 11
�Only treatment related adverse event are reported in this trial (Priotto 2009) [16]
#Adverse event recorded in NECT phase III trial [16] and in NECT MSF [19] have not been coded with MedDRA dictionary
$In NECT phase III [16], nausea and vomiting were reported together and not differentiated
“-”AE term not reported in the respective publication
https://doi.org/10.1371/journal.pntd.0008028.t005
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In a further step and in order to improve and generalize the proposed list, analyses of the
concomitant drugs used during fexinidazole [10] and acoziborole (registered under clinical-
trials.gov: NCT03087955) trials for second stage sleeping sickness patients shall be performed
in a near future.
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